Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences
- Investor call and webcast scheduled for Monday, November 14 at 8:00 a.m. EST
- Roivant will present at investor conferences in November
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. EST on Monday, November 14, 2022 to report its financial results for the second quarter ended September 30, 2022 and provide a corporate update.
To access the conference call by phone, please register online using this A webcast of the call will also be available under “Events & Presentations” in the Investors section of the Roivant website at . The archived webcast will be available on Roivant’s website after the conference call.
In addition, Roivant will participate in three upcoming investor conferences:
- Credit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes, CA from November 7-10. CFO Richard Pulik will present at 7:25 p.m. EST (4:25 p.m. PST) on Tuesday, November 8.
- Jefferies 2022 London Healthcare Conference in London from November 15-17. CEO Matt Gline will present at 10:15 a.m. EST (3:15 p.m. GMT) on Tuesday, November 15.
- Evercore ISI HealthCONx Conference, held virtually from November 29-December 1. CEO Matt Gline will present at 4:20 p.m. EST on Wednesday, November 30.
A live webcast of each presentation will be available under “Events & Presentations” on the Investors section of the Roivant website at and an archived recording will be available after the presentation.
About Roivant Sciences
Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch 'Vants' – nimble and focused biopharmaceutical and health technology companies. For more information, please visit .
Roivant Sciences Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are usually identified by the use of words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.
Contacts Investors Roivant Investor Relations Media Paul Davis Roivant Sciences
